Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. APTrans is a Cheshire-based consortium of drug development companies.
For Evgen, this agreement is a flexible way to get specialist technical and operational support for its drug.
Dr Stephen Franklin, Founder and CEO of Evgen Pharma, said: “We selected this excellent group of providers as our partners as they have a proven track record of working well together and they are all co-located at the Biohub where we too have a presence.”
Ned Wakeman, Director, Biohub at Alderley Park, said that the companies : “The companies within APTrans all spun out from AstraZeneca, participated in business acceleration programmes, and are thriving in their own right. We are passionate about nurturing an open and collaborative environment where like-minded companies can work, socialise and support each other, and are proud to share in the combined successes of these great companies.“